Compare UPC & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPC | SXTP |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.6M |
| IPO Year | 2020 | 2023 |
| Metric | UPC | SXTP |
|---|---|---|
| Price | $4.03 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.10 |
| AVG Volume (30 Days) | ★ 95.3K | 48.9K |
| Earning Date | 01-29-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,005,471.00 |
| Revenue This Year | N/A | $33.92 |
| Revenue Next Year | N/A | $51.35 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.49 |
| 52 Week Low | $2.00 | $0.34 |
| 52 Week High | $17.96 | $8.62 |
| Indicator | UPC | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 30.68 |
| Support Level | $2.57 | $0.45 |
| Resistance Level | $4.71 | $1.12 |
| Average True Range (ATR) | 0.58 | 0.09 |
| MACD | -0.15 | -0.00 |
| Stochastic Oscillator | 27.84 | 13.79 |
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.